Drug Interactions of Newer Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban with Routinely Used Nonanticoagulant/Antiplatelet Drugs

被引：0
|
作者：
Sayani, Shermin [1 ]
Iqbal, Omer [1 ]
Hoppensteadt, Debra [1 ]
Fareed, Jawed [1 ]
机构：
[1] Loyola Univ, Med Ctr, Maywood, IL 60153 USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 48 条
  • [21] Clinically relevant drug interactions between newer antidepressants and oral anticoagulants
    Spina, Edoardo
    Barbieri, Maria Antonietta
    Cicala, Giuseppe
    Bruno, Antonio
    de Leon, Jose
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2020, 16 (01) : 31 - 44
  • [22] A nationwide Belgian survey on the influence of the new oral anticoagulants dabigatran and rivaroxaban on commonly used coagulation assays
    Van Blerk, M.
    Bailleul, E.
    Chatelain, B.
    Demulder, A.
    Devreese, K.
    Douxfils, J.
    Jochmans, K.
    Mullier, F.
    Wijns, W.
    Soumali, M. R.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 263 - 263
  • [23] Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) Versus Warfarin in Patients With Atrial Fibrillation
    Miller, Corey S.
    Grandi, Sonia M.
    Shimony, Avi
    Filion, Kristian B.
    Eisenberg, Mark J.
    AMERICAN JOURNAL OF CARDIOLOGY, 2012, 110 (03): : 453 - 460
  • [24] SYSTEMATIC ASSESSMENT OF THE EFFECT OF DIRECT ORAL ANTICOAGULANTS DABIGATRAN, RIVAROXABAN AND APIXABAN USING CALIBRATED AUTOMATED THROMBIN GENERATION ASSAY IN VIVO
    Artang, Ramin
    Anderson, Maren
    Riley, Paul
    Nielsen, Joern Dalsgaard
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 768 - 768
  • [25] COST EFFECTIVENESS OF ORAL ANTICOAGULATION THERAPY FOR NON-VALVULAR ATRIAL FIBRILLATION PATIENTS: WARFARIN VERSUS THE NEW ORAL ANTICOAGULANTS RIVAROXABAN, DABIGATRAN AND APIXABAN
    Ortiz-Cartagena, Ismael
    Gotay, Antonio Orraca
    Acevedo, Jose
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 490 - 490
  • [26] A simple and fast HPLC-MS/MS method for simultaneous determination of direct oral anticoagulants apixaban, dabigatran, rivaroxaban in human plasma
    Lagoutte-Renosi, Jennifer
    Le Poupon, Julien
    Girard, Alexandra
    Montange, Damien
    Davani, Siamak
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2018, 1100 : 43 - 49
  • [27] In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein
    Margelidon-Cozzolino, Victor
    Hodin, Sophie
    Jacqueroux, Elodie
    Delezay, Olivier
    Bertoletti, Laurent
    Delavenne, Xavier
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2018, 365 (03): : 519 - 525
  • [28] Comparing new oral anticoagulants (dabigatran, rivaroxaban and apixaban) to warfarin in patients with atrial fibrillation, a cost-effectiveness analysis from a German payer perspective
    Krejczy, M.
    Wehling, M.
    Marx, S.
    Obermann, K.
    Harenberg, J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 256 - 257
  • [29] New oral anticoagulants - will they be used with antiplatelet drugs in patients with atrial fibrillation after acute coronary syndrome?
    Gorczyca-Michta, Iwona
    Wozakowska-Kaplon, Beata
    POSTEPY W KARDIOLOGII INTERWENCYJNEJ, 2013, 9 (04): : 348 - 352
  • [30] Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis
    Cohen, A. T.
    Hamilton, M.
    Bird, A.
    Mitchell, S. A.
    Li, S.
    Horblyuk, R.
    Batson, S.
    PLOS ONE, 2016, 11 (08):
12345